Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Approvable letter for SnET2 for AMD

Oct. 5, 2004

ISTA and Allergan sign new Vitrase agreement

Oct. 4, 2004

Expanded phase II trial for squalamine opens enrollment

Oct. 1, 2004

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

The EMEA accepts marketing authorization application for Macugen

Sep. 23, 2004

Approvable letter for Extravan for glaucoma

Sep. 21, 2004

Novel VAP-1 inhibitors and their use in macular edema described by Fujisawa

Sep. 15, 2004

Sirna Therapeutics files IND to advance Sirna-027 into clinic

Sep. 9, 2004

Gatiflo eye drops launched in Japan

Sep. 8, 2004

Macugen NDA accepted for review

Aug. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...